Interactions between Anti-VEGF Therapy and Antitumor Immunity as a Ptentional Therapeutic Strategy in Colorectal Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27283933%3A_____%2F19%3A00006948" target="_blank" >RIV/27283933:_____/19:00006948 - isvavai.cz</a>

Výsledek na webu

<a href="https://actamedica.lfhk.cuni.cz/62/3/0127/" target="_blank" >https://actamedica.lfhk.cuni.cz/62/3/0127/</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Interactions between Anti-VEGF Therapy and Antitumor Immunity as a Ptentional Therapeutic Strategy in Colorectal Cancer

Popis výsledku v původním jazyce

There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by CEGF on effector T cells. Bearing in mind th recent advanced of combination immunotherapy, combination of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementaion of a combination strategy for treating cancer is understading the interaction of these two therapeutic interventions, particularly in regards to appropiate reprogramming of the tumor immune microenviromet to improve antitumor immunity

Název v anglickém jazyce

Interactions between Anti-VEGF Therapy and Antitumor Immunity as a Ptentional Therapeutic Strategy in Colorectal Cancer

Popis výsledku anglicky

There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by CEGF on effector T cells. Bearing in mind th recent advanced of combination immunotherapy, combination of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementaion of a combination strategy for treating cancer is understading the interaction of these two therapeutic interventions, particularly in regards to appropiate reprogramming of the tumor immune microenviromet to improve antitumor immunity

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů